[go: up one dir, main page]

DE60008374D1 - Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten - Google Patents

Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten

Info

Publication number
DE60008374D1
DE60008374D1 DE60008374T DE60008374T DE60008374D1 DE 60008374 D1 DE60008374 D1 DE 60008374D1 DE 60008374 T DE60008374 T DE 60008374T DE 60008374 T DE60008374 T DE 60008374T DE 60008374 D1 DE60008374 D1 DE 60008374D1
Authority
DE
Germany
Prior art keywords
alpha
nmda antagonist
agonist
adrenergen
preparation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60008374T
Other languages
English (en)
Other versions
DE60008374T2 (de
Inventor
Nicholas Peter Franks
Mervyn Maze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protexeon Ltd
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60008374(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of DE60008374D1 publication Critical patent/DE60008374D1/de
Application granted granted Critical
Publication of DE60008374T2 publication Critical patent/DE60008374T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60008374T 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten Expired - Lifetime DE60008374T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
GB9913677 1999-06-11
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (2)

Publication Number Publication Date
DE60008374D1 true DE60008374D1 (de) 2004-03-25
DE60008374T2 DE60008374T2 (de) 2004-12-09

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008374T Expired - Lifetime DE60008374T2 (de) 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten

Country Status (14)

Country Link
US (1) US6562855B1 (de)
EP (1) EP1187635B1 (de)
JP (1) JP2003529541A (de)
AT (1) ATE259658T1 (de)
AU (1) AU778671B2 (de)
CA (1) CA2376916C (de)
DE (1) DE60008374T2 (de)
DK (1) DK1187635T3 (de)
ES (1) ES2215678T3 (de)
GB (2) GB9913677D0 (de)
PT (1) PT1187635E (de)
RU (1) RU2244558C2 (de)
WO (1) WO2000076545A1 (de)
ZA (1) ZA200110116B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
ES2321185T3 (es) 2002-06-12 2009-06-03 Air Liquide Deutschland Gmbh Proteccion cerebral con un gas que contiene xenon.
US20050255169A1 (en) * 2002-07-05 2005-11-17 Messer Griesheim Adjuvant containing xenon
WO2004052337A2 (de) * 2002-12-06 2004-06-24 Michael Georgieff Nasale pharmazeutische präparation enthaltend eine lipophile flüssige oder gasförmige wirksubstanz
CA2542412A1 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US8338421B2 (en) 2008-08-01 2012-12-25 Alpha Synergy Development, Inc. Compositions and methods for reversing rebound hyperemia
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
KR101859486B1 (ko) * 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
AU2011204315A1 (en) * 2010-01-08 2012-08-02 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
CN103068394A (zh) * 2010-04-15 2013-04-24 皇家学习促进学会/麦吉尔大学 对于疼痛的局部治疗
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
AU2014233018A1 (en) 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
RU2723761C1 (ru) 2016-10-31 2020-06-17 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6083720A (en) 1995-11-13 2000-07-04 Chroboczek; Jadwiga Dodecahedral adenoviral protein complex, composition containing same and uses thereof
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
CA2376916C (en) 2010-09-21
GB2352633B (en) 2002-04-17
AU778671B2 (en) 2004-12-16
AU5544400A (en) 2001-01-02
JP2003529541A (ja) 2003-10-07
GB9913677D0 (en) 1999-08-11
PT1187635E (pt) 2004-07-30
GB2352633A (en) 2001-02-07
ES2215678T3 (es) 2004-10-16
DK1187635T3 (da) 2004-06-21
GB0014165D0 (en) 2000-08-02
ATE259658T1 (de) 2004-03-15
EP1187635A1 (de) 2002-03-20
RU2244558C2 (ru) 2005-01-20
US6562855B1 (en) 2003-05-13
EP1187635B1 (de) 2004-02-18
DE60008374T2 (de) 2004-12-09
CA2376916A1 (en) 2000-12-21
ZA200110116B (en) 2003-07-23
WO2000076545A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
EP1762236A3 (de) Formulierungen von alpha-adrenergen Rezeptor-Antagonisten und ihre Anwendungen
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
MY129356A (en) Electrospun pharmaceutical compositions
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
GB2365772A (en) Factor
TR199800902T2 (xx) Ecza form�lasyonlar�.
SE9902386D0 (sv) New formulation
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60111265D1 (de) Pharmazeutische zusammensetzungen mit nmda-rezeptor-agonist
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ES2148493T3 (es) Nuevos compuestos con efecto analgesico y anestesico local.
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
DE60006788D1 (de) Iod-herstellungszusammensetzung
NO20010537D0 (no) Farmasöytiske preparater omfattende ibuprofen og domperidon
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings